Bloomin' Brands

Bloomin’ Brands continues to provide a high-level disclosure of its key purchased animal proteins in its Annual Reports (AR) and on its company website. In its 2023 AR, it stated that both pork and beef represent the majority of its purchased proteins in the US and Brazil. In its 2024 AR, the company now only states that beef represents the majority of its purchased protein in the US. The company also lists its other major commodities which include seafood, pork, poultry, and dairy but does not include eggs, however, the company has disclosed welfare commitments to ensure that eggs procured globally are 100% cage-free by 2030. Although the company states that beef is its most purchased protein in the US, it remains unclear how material each protein is to its global operations. It would be helpful to investors to see a granular breakdown using percentage or volume metrics.

Bloomin’ Brands has developed a materiality matrix where it has identified antibiotics as being moderately important to sustainability and slightly more important to its business success than managing climate risk. The company discloses that it only allows antibiotic use when medically necessary and under a veterinarian’s supervision. The company states that its policies align with guidelines from the World Health Organisation (WHO) and World Organisation for Animal Health (WOAH), however, these policies do not appear to be publicly available and therefore the company is considered to have no relevant disclosure for these criteria. The company does not disclose which specific guidance provided by the WHO and WOAH it is referring to or the extent of its alignment with these guidelines. It also remains unclear to investors which proteins, geographies and antibiotic classes are covered by its policies.

There is no relevant disclosure for this KPI as Bloomin’ Brands does not publicly disclose an antibiotics policy.

The company does not disclose levels of antibiotic use in its supply chain.

There is no evidence that the company audits its suppliers to ensure they align with its antibiotic requirements.

Bloomin’ Brands does not disclose any evidence of how it manages non-compliance with its antibiotic requirements.

Bloomin’ Brands does not publicly disclose an antibiotics reduction target.

Bloomin’ Brands does not publicly disclose an antibiotics reduction target.

Bloomin’ Brands does not publicly disclose an antibiotics reduction target.